Communications medicine最新文献

{"title":"Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.","authors":"Matteo Augello, Valeria Bono, Roberta Rovito, Alessandro Tavelli, Andrea Santoro, Camilla Tincati, Alessandra Vergori, Anna Maria Azzini, Elda Righi, Gianluca Spiteri, Stefano Porru, Silvia Meschi, Stefania Notari, Fabrizio Maggi, Andrea Antinori, Evelina Tacconelli, Antonella d'Arminio Monforte, Giulia Marchetti","doi":"10.1038/s43856-025-00799-6","DOIUrl":"10.1038/s43856-025-00799-6","url":null,"abstract":"<p><strong>Background: </strong>Variant-adapted vaccines are recommended in vulnerable populations to address the waning immunity and the emergence of immune-escaping SARS-CoV-2 variants, yet data about immune responses to such vaccines in people living with HIV (PLWH) are limited. We therefore aimed to assess long-term immune responses to an original-BA.4/5 mRNA booster in this population.</p><p><strong>Methods: </strong>In this prospective longitudinal study, PLWH receiving either an original-BA.4/5 bivalent booster or an original monovalent booster and HIV-negative healthcare workers (HCWs) receiving a bivalent booster were enrolled and sampled before (T0), 1 month (T1), and 4-9 months (T2) after the vaccine administration. SARS-CoV-2-specific T and B cells, RBD-binding antibodies, and RBD-blocking antibodies against both wild type (WT) and omicron BA.4/5 virus were determined.</p><p><strong>Results: </strong>The bivalent booster is able to transiently increase both humoral and polyfunctional T cell responses in PLWH, with humoral responses comparable to those observed in HCWs. While T cell responses are cross-reactive against viral variants and stable over time, humoral immunity is imprinted to the ancestral virus and wanes quickly. Furthermore, whilst previous SARS-CoV-2 infection does not affect the trajectory of vaccine-elicited immune responses, markers of HIV-related T cell dysfunction are associated with lower antibody peak responses and higher antibody waning. Lastly, the bivalent booster was superior to the monovalent one in inducing BA.4/5-reactive RBD-blocking antibodies.</p><p><strong>Conclusions: </strong>The original-BA.4/5 bivalent booster is highly immunogenic in PLWH and superior to the monovalent one in inducing humoral responses against the BA.4/5 virus, although HIV-related T cell dysfunction markers are associated with blunted and less durable antibody immunity.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"92"},"PeriodicalIF":5.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model.","authors":"Muhammad S Khan, Douglas Smego, Jing Li, Yuki Ishidoya, Emmanuel Offei, Martha Sofia Ruiz Castillo, Annie M Hirahara, Pia Balmaceda, Jennifer Hunter, Anand Athavale, Monica P Revelo, Joseph A Palatinus, Craig H Selzman, Ravi Ranjan, TingTing Hong, Derek J Dosdall, Robin M Shaw","doi":"10.1038/s43856-025-00787-w","DOIUrl":"10.1038/s43856-025-00787-w","url":null,"abstract":"<p><strong>Background: </strong>Ischemic cardiomyopathy and resultant heart failure (HF) is a significant cause of morbidity and mortality worldwide. Downregulation of cardiac bridging integrator 1 (cBIN1), a membrane scaffolding protein responsible for organizing t-tubules and organizing the calcium handing apparatus, occurs in progressive HF. Therefore, gene therapy upregulating cBIN1 production may rescue failing muscle and clinical HF.</p><p><strong>Methods: </strong>Adult mongrel dogs underwent ligation of the left anterior descending artery and developed progressive dilated cardiomyopathy and chronic HF. When left ventricular ejection fraction (LVEF) dropped below 40%, the animals received a one-time series of endocardial injections of either of low dose gene therapy composed of either adeno-associated virus serotype 9 packaged cBIN1 (AAV9-cBIN1, n = 6) or AAV9-GFP (green fluorescent protein, n = 4). Animals were followed up to 7 weeks after therapy delivery with laboratory, echocardiography, and endocardial mapping assessment.</p><p><strong>Results: </strong>Post injection of the negative control, animals develop progressive symptomatic HF requiring early termination of all but one animal prior to the end of the study. In contrast, the AAV9-cBIN1-treated group reveals a significant improvement in LV function, with a noticeable improvement in LVEF (29 ± 3% vs. 42 ± 2%, p = 0.0095) and global longitudinal strain (-7.1 ± 0.9% vs. -12.5 ± 1.6%, p = 0.0095). Compared to the control animals, the AAV9-cBIN1-treated group displays improved T-tubule morphology, left ventricular chamber size, plasma biomarkers, and endocardial voltage, and survives the study period.</p><p><strong>Conclusions: </strong>Chronic HF from ischemic cardiomyopathy can be successfully treated with low dose AAV9-cBIN1 gene therapy. This study indicates that myocardial specific therapy can dramatically reverse HF progression.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"93"},"PeriodicalIF":5.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactation duration and ischemic heart disease among parous postmenopausal females from a prospective cohort study.","authors":"Leying Hou, Shiyi Shan, Keyao Lu, Weidi Sun, Wen Liu, Xue Li, Changzheng Yuan, Peige Song","doi":"10.1038/s43856-025-00806-w","DOIUrl":"10.1038/s43856-025-00806-w","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the association of lactation duration with incident ischemic heart disease (IHD) and to determine the potential health gains from scaling up breastfeeding practice.</p><p><strong>Methods: </strong>130,147 parous postmenopausal females without IHD were included at baseline (2004-2008) from the China Kadoorie Biobank study. Lactation duration was self-reported and measured as lifetime, per child, and first child, respectively. Incident IHD was identified during follow-up (2004-2015). The dose-response associations between lactation duration and IHD were examined using Cox models with restricted cubic splines. Stratification analyses were conducted by socioeconomic status (SES) and residence. The number of preventable IHD cases was estimated using the population attributable fraction and potential impact fraction in various scenarios.</p><p><strong>Results: </strong>The study shows that parous postmenopausal females who ever lactated have significantly lower risks of IHD, with adjusted hazard ratios (aHRs) varying from 0.71 (95%CI: 0.63-0.80) to 0.85 (95%CI: 0.75-0.96) for a lifetime, from 0.70 (0.63-0.78) to 0.82 (0.72-0.93) for per-child, and from 0.80 (0.74-0.87) to 0.92 (0.85-0.99) for the first-child, appearing as U-shaped associations. Similar associations are found in females with low SES and urban residence. The scaling up of breastfeeding to near-universal levels could have prevented up to 115,000 new IHD cases among Chinese females aged over 40 years in 2019.</p><p><strong>Conclusions: </strong>Lactation demonstrates potential benefits in reducing IHD risk, appearing as U-shaped associations among Chinese parous postmenopausal females, especially for those with low SES in urban areas. Scaling up breastfeeding practices serves as a promising strategy for reducing the IHD burden in China.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"86"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term risk of malignancies in persons with ischemic heart disease treated with trimetazidine dihydrochloride.","authors":"Yuen-Ting Cheng, Chun-Fung Sin, Edmond S K Ma, Stephen T S Lam, Shiu-Lun Au Yeung, Bernard M Y Cheung, Hung-Fat Tse, Kai-Hang Yiu, Yap-Hang Chan","doi":"10.1038/s43856-025-00805-x","DOIUrl":"10.1038/s43856-025-00805-x","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming of energy processes is a cellular hallmark of various cancers. Whether trimetazidine, an anti-ischemic agent that preferentially potentiates cellular glucose oxidation, alters the long-term risk of malignancies is unknown.</p><p><strong>Methods: </strong>In this multi-center, retrospective cohort study, we studied the effect of trimetazidine on new-onset malignancies in 200,563 ischemic heart disease patients (mean age 70.8 years, 46.6% female) using the Hong Kong Clinical Data Analysis and Reporting System (CDARS), comparing trimetazidine users (n = 16,873) to nitrate users (n = 183,690, as control) over at least 30 days. The primary endpoint was defined as the estimated effect of trimetazidine on the overall new-onset occurrence of any malignancies a priori specified, diagnosed 90 days or more after the cohort entry.</p><p><strong>Results: </strong>Over a mean follow-up duration of 8.36 (6.42) years, the incidence rate of new-onset malignancies amongst trimetazidine users is significantly lower compared to the non-users (8.76 vs 12.3 per 1000-person years, trimetazidine to control incidence ratio, 0.71). Trimetazidine use is associated with improved event-free survival from new-onset malignancies (Mean survival: 231 [0.53] versus 225 [0.21] months, Chi-square = 161, P < 0.001). Multivariable Cox regression demonstrates an independently lower risk of new-onset malignancies associated with trimetazidine use, with (adjusted HRs, 0.71, 95% CI, 0.66-0.77, P < 0.001) and without (adjusted HRs, 0.71, 95% CI, 0.68-0.75, P < 0.001) propensity score matching. Subgroup analyses of new-onset malignancies including lung, colorectal, hepatobiliary & pancreatic, breast, stomach & oesophageal, renal & genito-urinary, prostate, and hematological malignancies, show similar risk reductions.</p><p><strong>Conclusions: </strong>Modulation of metabolic reprogramming may represent a new therapeutic target for cancer prevention.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"89"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer.","authors":"Sarah B Gitto, Austin R Pantel, Kara N Maxwell, Daniel A Pryma, Michael D Farwell, Fang Liu, Quy Cao, Sophia R O'Brien, Amy S Clark, Payal D Shah, Elizabeth S McDonald","doi":"10.1038/s43856-025-00791-0","DOIUrl":"10.1038/s43856-025-00791-0","url":null,"abstract":"<p><strong>Background: </strong>Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) breast cancers. Yet, response in these populations remains variable, suggesting clinical utility in developing a better biomarker to select patients for PARPi and predict response. Here, we evaluate a radiolabeled PARPi, [¹⁸F]FluorThanatrace ([¹⁸F]FTT), as a functional biomarker of PARPi response in breast cancer.</p><p><strong>Methods: </strong>A single-arm prospective observational trial was conducted at the University of Pennsylvania. [¹⁸F]FTT-PET uptake was measured in 24 women with untreated primary breast cancer and correlated with tumor HRD score. In a separate cohort of ten subjects with metastatic HER- breast cancer, [¹⁸F]FTT-PET uptake was measured at baseline and after a short interval on a PARPi (a measure of drug-target engagement) and correlated to progression free survival (PFS).</p><p><strong>Results: </strong>Here we show that baseline [¹⁸F]FTT-PET uptake does not correlate to HRD tissue score, supporting that [¹⁸F]FTT provides distinct information from genetic features. Baseline [¹⁸F]FTT-PET uptake and the change in uptake from baseline to after PARPi initiation significantly correlates to PFS in woman with breast cancer who received a PARPi (ρ = 0.74, P = 0.023 and ρ = -0.86, P = 0.012, respectively).</p><p><strong>Conclusions: </strong>These early results suggest the potential of [¹⁸F]FTT-PET to select patients for PARPi treatment and monitor in vivo pharmacodynamics after therapy start. Absence of association with HRD scores supports [¹⁸F]FTT uptake as a novel measure that may be leveraged as a biomarker. Further studies are warranted.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"90"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized cerebellar damage predicts the presence of behavioral disorders in children with brainstem tumors.","authors":"Heyuan Jia, Kaikai Wang, Mingxin Zhang, Guocan Gu, Yiying Mai, Xia Wu, Congying Chu, Xuntao Yin, Peng Zhang, Lingzhong Fan, Liwei Zhang","doi":"10.1038/s43856-025-00810-0","DOIUrl":"10.1038/s43856-025-00810-0","url":null,"abstract":"<p><strong>Background: </strong>Brainstem tumors often cause intractable neurobehavioral issues, which can be a challenge for patients and surgeons. Research on cerebellar changes in these patients is limited, despite symptoms similar to cerebellar injuries. This study aims to investigate cerebellar damage pattern resulting from brainstem tumors and its association with behavioral disorders.</p><p><strong>Methods: </strong>This study enrolled 147 children with brainstem tumors. A U-Net-based segmentation algorithm is used to divide their cerebellums into 26 lobules. And these lobules are then used to build a normative model for assessing individual structural deviations. Furthermore, a behavior prediction model is developed using the total outlier count (tOC) index and cerebellar lobule volume as predictive features.</p><p><strong>Results: </strong>Over 95% of patients are found to have negative deviations in cerebellar regions, particularly in anterior lobules like Left V. Higher tOC is significantly associated with severe social problems (r = 0.31, p = 0.001) and withdrawal behavior (r = 0.28, p = 0.001). Smaller size of cerebellar regions strongly correlates with more pronounced social problems (r = 0.27, p = 0.007) and withdrawal behavior (r = 0.25, p = 0.015). Notably, lobules Right X, V, IV, VIIB, Left IX, VIII, and X influence social problems, while Left V, Right IV, Vermis VI, and VIII impact withdrawal behavior.</p><p><strong>Conclusions: </strong>Our study reveals cerebellar damage patterns in patients with brainstem tumors, emphasizing the role of both anterior and posterior cerebellar lobes in social problems and withdrawal behavior. This research sheds light on the cerebro-brainstem-cerebellar underlying complex behavioral disorders in brainstem tumor patients.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"91"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France.","authors":"Michaël Falguières, Eva Hong, Mélanie Denizon, Aude Terrade, Muhamed-Kheir Taha, Ala-Eddine Deghmane","doi":"10.1038/s43856-025-00800-2","DOIUrl":"10.1038/s43856-025-00800-2","url":null,"abstract":"<p><strong>Background: </strong>Invasive meningococcal disease (IMD) of serogroup B is preventable by protein-based vaccines targeting one (Bivalent rLP2086 vaccine) or several variable proteins (4CMenB vaccine) at the bacterial surface. The 4CMenB was licensed in Europe in 2013 but has been recommended and reimbursed in France for infants over 2 months old since April 2022. The bivalent rLP2086 vaccine was licensed in Europe in 2017 for subjects of 10 years and older. Evaluating strain coverage and fluctuations prior to large scale vaccine use is highly informative.</p><p><strong>Methods: </strong>We analysed invasive isolates at the French National Reference Centre for meningococci between 1975 and 2022. The 1691 recovered isolates were sequenced. We scored sex, and age groups of subjects. We also scored clonal complexes (CC) and the predicted coverage rates of the corresponding isolates using the genetic Meningococcal Antigen Typing System (gMATS) and the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR).</p><p><strong>Results: </strong>The period was divided into four periods 1975-1986, 1987-1998-1999-2010 and 2011-2022. Our data clearly show significant differences in the distribution of alleles encoding the vaccine-covered antigens between these four periods. The clonal complex (CC) distribution also differed between the two periods with the disappearance of CC8 since 2011 and drastic decreases in CC11 since 1999. MenDeVar-predicted coverage fluctuated between 46.8% and 60.6% during the four periods for the 4CMenB and between 63.4% and 81.3% for rLP2086. For 4CMenB, coverage was higher using gMATS and varied between 74.5% and 85.0%. Fluctuations were also observed for all age groups.</p><p><strong>Conclusions: </strong>IMD epidemiology is continuously changing with fluctuation in vaccine strain coverage over the 48 years prior to the routine implementation of the vaccines.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"87"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Derivation and validation of a non-invasive optoacoustic imaging biomarker for detection of patients with intermittent claudication.","authors":"Milenko Caranovic, Julius Kempf, Yi Li, Adrian P Regensburger, Josefine S Günther, Anna P Träger, Werner Lang, Alexander Meyer, Alexandra L Wagner, Joachim Woelfle, Roman Raming, Lars-Philip Paulus, Adrian Buehler, Wolfgang Uter, Michael Uder, Christian-Alexander Behrendt, Markus F Neurath, Maximilian J Waldner, Ferdinand Knieling, Ulrich Rother","doi":"10.1038/s43856-025-00801-1","DOIUrl":"10.1038/s43856-025-00801-1","url":null,"abstract":"<p><strong>Background: </strong>Peripheral arterial disease (PAD) affects more than 200 million people worldwide, with symptoms ranging from none to severe. Despite these different diagnostic options, patients with unclear leg pain remain challenging to diagnose. The primary objective of this study was to evaluate whether multispectral optoacoustic tomography (MSOT) can discriminate between healthy volunteers (HV) and patients with intermittent claudication (IC) by assessing hemoglobin-related biomarkers in calf muscle tissue.</p><p><strong>Method: </strong>In this monocentric, cross-sectional, observational diagnostic trial (NCT05373927) n = 102 patients were included in two independent derivation (DC, n = 51) and validation cohorts (VC, n = 51). MSOT was performed before and after standardized heel raise provocation and was compared to standardized PAD diagnostics including pulse palpation, ankle brachial index (ABI), duplex sonography, 6-minute walk test (6MWT), assessment of health-related quality of life (VASCUQOL-6), and angiography (aggregated TransAtlantic Inter-Society Consensus classification, aTASC).</p><p><strong>Results: </strong>Here we show that MSOT is capable of differentiating IC and HV with an area under the receiver operator characteristics curve (AUROC) in DC by 0.99 (sensitivity: 100%, specificity: 95.8%) and in the VC by 0.95 (sensitivity: 96.2%, specificity: 96.0%). MSOT-derived oxygenation positively correlates with the ABI post-exercise (R = 0.83, P = 2.31 × 10^-26), the absolute walking distance in the 6MWT (R = 0.77, P = 3.40 × 10^-21), the VASCUQOL-6 (R = 0.79, P = 4.82 × 10^-23) and negatively with aTASC classification (R = -0.80, P = 2.92 × 10^-24).</p><p><strong>Conclusions: </strong>Post-exercise MSOT-derived saturation in the calf muscle is validated as a non-invasive imaging biomarker to distinguish HV and IC patients yielding high sensitivity and specificity.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"88"},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination for prevention of hearing loss: a scoping review.","authors":"Mira Johri, Shoghig Téhinian, Myriam Cielo Pérez Osorio, Enis Barış, Brian Wahl","doi":"10.1038/s43856-025-00795-w","DOIUrl":"10.1038/s43856-025-00795-w","url":null,"abstract":"<p><strong>Background: </strong>Infectious diseases in childhood and adolescence are significant and often preventable causes of hearing loss, especially in low- and middle-income countries. We conducted a scoping review to examine the extent, range and nature of available evidence on the role of vaccination for prevention of hearing loss worldwide.</p><p><strong>Methods: </strong>We reviewed the published scientific literature to identify studies providing quantitative information on the relationship between vaccination and hearing loss. We searched four databases: MEDLINE, EMBASE, Cochrane Library and Global Index Medicus. No date, language, or geographical restrictions were imposed. Two independent reviewers assessed eligibility and charted data.</p><p><strong>Results: </strong>Here we show that vaccination may be a key, underexploited strategy for primary prevention of child and adolescent hearing loss. Although the important contributions of rubella and meningitis vaccinations to hearing loss prevention are widely recognised, we identify 26 distinct known or potential infectious causes of hearing loss that are preventable or possibly preventable through vaccination. Notwithstanding, we find a dearth of empirical evidence on the impacts of vaccination on hearing loss prevention. In addition, the review identifies no research from low- and middle-income countries, which bear the overwhelming burden of child and adolescent hearing loss. Finally, it shows that numerous vaccines that address priority infectious diseases relevant to hearing loss are in development and could be brought into use.</p><p><strong>Conclusions: </strong>We recommend strategic investment in research concerning vaccination as a strategy for primary prevention of child and adolescent hearing loss.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"85"},"PeriodicalIF":5.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A one health approach to improve the safety of traditional yak blood drinking in Nepal.","authors":"Krishna Prasad Acharya, Sarita Phuyal, AbdulRahman A Saied","doi":"10.1038/s43856-025-00763-4","DOIUrl":"10.1038/s43856-025-00763-4","url":null,"abstract":"","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"84"},"PeriodicalIF":5.4,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}